Results 211 to 220 of about 55,045 (296)

Hormonal replacement therapy in postmenopausal women ≥50 years is associated with the incidence of glaucoma: Evidence from 6576 females in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose Hormonal replacement therapy (HRT) in postmenopausal women appears to affect glaucoma risk, but findings are inconsistent. We aimed to explore whether the use of postmenopausal HRT plays a role in glaucoma development in Finland. Methods The main outcome variable was glaucoma incidence measured by initiation of special reimbursement ...
Sirpa Loukovaara, Jari Haukka
wiley   +1 more source

Analysis of Menopausal Hormone Therapy to Chinese Patients with Menopausal Syndrome: A Real-World Retrospective Study from Chinese Hospitals. [PDF]

Drug Des Devel Ther
Zhu Z, Shi A, Liu L, Jin G, Wang X.
europepmc   +1 more source

Genetic risk factors in Finnish patients with Fuchs endothelial corneal dystrophy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To study the genetic risk factors of Fuchs endothelial corneal dystrophy (FECD) in the Finnish population using hospital‐based and large biobank cohorts. Methods We genotyped a cohort of 107 Finnish patients with FECD for the primary associated genetic risk factor, the TCF4 (CTG)>50 expansion, and studied their clinical phenotype.
Inka‐Tuulevi Vähämäki, Annamari T. Immonen, Joel T. Rämö, Aino M. Jaakkola, Kari Krootila, Maria Kaukonen, FinnGen, Aarno Palotie, Hannes Lohi, Tero T. Kivelä, Joni A. Turunen   +10 more
wiley   +1 more source

Instrumental Variables Methods Reveal Larger Effects of Menopausal Hormone Therapy in the Landmark Women's Health Initiative Clinical Trial. [PDF]

AEA Pap Proc
Angrist J, Kowalski AE, Ristovska L, Stefanick ML.   +3 more
europepmc   +1 more source

Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert, Louise N. Nolan, Katja M. Schmalenberger   +2 more
wiley   +1 more source

Position paper of the expert panel of the Polish Society of Menopause and Andropause on the use of Oestrogel^® in menopausal hormone therapy^. [PDF]

Prz Menopauzalny
Bińkowska M, Paszkowski T, Skrzypulec-Plinta V, Zgliczyński W.   +3 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. [PDF]

JNCI Cancer Spectr
MacInnis RJ, Jenkins MA, Milne RL, John EM, Daly MB, Andrulis IL, Colonna SV, Phillips KA, kConFab Investigators, Le Marchand L, Newcomb PA, Phipps AI, Schmit SL, Macrae FA, Buchanan DD, Gallinger S, Pai RK, Samadder NJ, Giles GG, Southey MC, Hopper JL, Terry MB.   +21 more
europepmc   +1 more source

Serum Estradiol Concentrations With Estradiol 0.06% Gel in Transgender and Gender‐Diverse Adults

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Transgender and gender‐diverse individuals undergoing estradiol therapy for gender affirmation are typically treated with oral or transdermal estradiol, with transdermal estradiol recommended for those aged > 45 years. There are limited data evaluating estradiol gel in gender‐affirming hormone therapy regimens. We aimed to assess the
Raquel A. Maggacis, Ada S. Cheung, Brendan J. Nolan   +2 more
wiley   +1 more source

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh, Nathalie Vermeulen, Carolyn Ee, Helena Teede, Amanda J. Vincent   +4 more
wiley   +1 more source